Boosted selective internal radiation therapy with ^sup 90^Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept
To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with ^sup 90^Y-loaded glass microspheres (TheraSphere). TheraSphere was administered to 71 patients with...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2013-07, Vol.40 (7), p.1057 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 1057 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 40 |
| creator | Garin, E Lenoir, L Edeline, J Laffont, S Mesbah, H Porée, P Sulpice, L Boudjema, K Mesbah, M Guillygomarc'h, A Quehen, E Pracht, M Raoul, J L Clement, B Rolland, Y Boucher, E |
| description | To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with ^sup 90^Y-loaded glass microspheres (TheraSphere). TheraSphere was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n=6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved.[PUBLICATION ABSTRACT] |
| doi_str_mv | 10.1007/s00259-013-2395-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1366562400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2993321601</sourcerecordid><originalsourceid>FETCH-proquest_journals_13665624003</originalsourceid><addsrcrecordid>eNqNjr1OAzEQhC0EEuHnAehWooHCsL4jlxxlUBC0kIYmkeXb5Bz5bOP1EeCReEoOCVFTzWj0ze4IcabwSiFOrhmxGNcSVSmLsh7L9z0xUpWq5QSn9f6fn-ChOGLeIqppMa1H4msWAmdqgMmRyfaNwPpMyWsHSTdWZxs85JaSjh-ws7mFJfcRaly-SBd0M1Q3TjNDZ00KHAeSGC5m8vnxaXEJ65CgpahzMORc73QCo5OxPnQahtiSz3wLGjztIFLiMHy2n8PVmEJn2foNmOANxXwiDtbaMZ3-6rE4v58v7h7kQL72xHm1Df3PcF6psqrGVXGDWP6P-gZZ0WeI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1366562400</pqid></control><display><type>article</type><title>Boosted selective internal radiation therapy with ^sup 90^Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept</title><source>Springer Nature - Complete Springer Journals</source><creator>Garin, E ; Lenoir, L ; Edeline, J ; Laffont, S ; Mesbah, H ; Porée, P ; Sulpice, L ; Boudjema, K ; Mesbah, M ; Guillygomarc'h, A ; Quehen, E ; Pracht, M ; Raoul, J L ; Clement, B ; Rolland, Y ; Boucher, E</creator><creatorcontrib>Garin, E ; Lenoir, L ; Edeline, J ; Laffont, S ; Mesbah, H ; Porée, P ; Sulpice, L ; Boudjema, K ; Mesbah, M ; Guillygomarc'h, A ; Quehen, E ; Pracht, M ; Raoul, J L ; Clement, B ; Rolland, Y ; Boucher, E</creatorcontrib><description>To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with ^sup 90^Y-loaded glass microspheres (TheraSphere). TheraSphere was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p<0.001). With a threshold TD of 205 Gy, MAA SPECT/CT predicted response with a sensitivity of 100 % and overall accuracy of 90 %. Based on TD and HILD, 17 patients underwent treatment intensification resulting in a good response rate (76.4 %), without increased grade III liver toxicity. The median TTP and OS were 5.5 months (2-9.5 months) and 11.5 months (2-31 months), respectively, in patients with TD <205 Gy and 13 months (10-16 months) and 23.2 months (17.5-28.5 months), respectively, in those with TD >205 Gy (p=0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n=33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD <205 Gy and 10 months (6-15.2 months) and 21.5 months (12-28.5 months), respectively, in those with TD >205 Gy (p=0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n=6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-013-2395-x</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><subject>Cancer ; Patients ; Radiation therapy</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2013-07, Vol.40 (7), p.1057</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Garin, E</creatorcontrib><creatorcontrib>Lenoir, L</creatorcontrib><creatorcontrib>Edeline, J</creatorcontrib><creatorcontrib>Laffont, S</creatorcontrib><creatorcontrib>Mesbah, H</creatorcontrib><creatorcontrib>Porée, P</creatorcontrib><creatorcontrib>Sulpice, L</creatorcontrib><creatorcontrib>Boudjema, K</creatorcontrib><creatorcontrib>Mesbah, M</creatorcontrib><creatorcontrib>Guillygomarc'h, A</creatorcontrib><creatorcontrib>Quehen, E</creatorcontrib><creatorcontrib>Pracht, M</creatorcontrib><creatorcontrib>Raoul, J L</creatorcontrib><creatorcontrib>Clement, B</creatorcontrib><creatorcontrib>Rolland, Y</creatorcontrib><creatorcontrib>Boucher, E</creatorcontrib><title>Boosted selective internal radiation therapy with ^sup 90^Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept</title><title>European journal of nuclear medicine and molecular imaging</title><description>To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with ^sup 90^Y-loaded glass microspheres (TheraSphere). TheraSphere was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p<0.001). With a threshold TD of 205 Gy, MAA SPECT/CT predicted response with a sensitivity of 100 % and overall accuracy of 90 %. Based on TD and HILD, 17 patients underwent treatment intensification resulting in a good response rate (76.4 %), without increased grade III liver toxicity. The median TTP and OS were 5.5 months (2-9.5 months) and 11.5 months (2-31 months), respectively, in patients with TD <205 Gy and 13 months (10-16 months) and 23.2 months (17.5-28.5 months), respectively, in those with TD >205 Gy (p=0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n=33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD <205 Gy and 10 months (6-15.2 months) and 21.5 months (12-28.5 months), respectively, in those with TD >205 Gy (p=0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n=6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved.[PUBLICATION ABSTRACT]</description><subject>Cancer</subject><subject>Patients</subject><subject>Radiation therapy</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNjr1OAzEQhC0EEuHnAehWooHCsL4jlxxlUBC0kIYmkeXb5Bz5bOP1EeCReEoOCVFTzWj0ze4IcabwSiFOrhmxGNcSVSmLsh7L9z0xUpWq5QSn9f6fn-ChOGLeIqppMa1H4msWAmdqgMmRyfaNwPpMyWsHSTdWZxs85JaSjh-ws7mFJfcRaly-SBd0M1Q3TjNDZ00KHAeSGC5m8vnxaXEJ65CgpahzMORc73QCo5OxPnQahtiSz3wLGjztIFLiMHy2n8PVmEJn2foNmOANxXwiDtbaMZ3-6rE4v58v7h7kQL72xHm1Df3PcF6psqrGVXGDWP6P-gZZ0WeI</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Garin, E</creator><creator>Lenoir, L</creator><creator>Edeline, J</creator><creator>Laffont, S</creator><creator>Mesbah, H</creator><creator>Porée, P</creator><creator>Sulpice, L</creator><creator>Boudjema, K</creator><creator>Mesbah, M</creator><creator>Guillygomarc'h, A</creator><creator>Quehen, E</creator><creator>Pracht, M</creator><creator>Raoul, J L</creator><creator>Clement, B</creator><creator>Rolland, Y</creator><creator>Boucher, E</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20130701</creationdate><title>Boosted selective internal radiation therapy with ^sup 90^Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept</title><author>Garin, E ; Lenoir, L ; Edeline, J ; Laffont, S ; Mesbah, H ; Porée, P ; Sulpice, L ; Boudjema, K ; Mesbah, M ; Guillygomarc'h, A ; Quehen, E ; Pracht, M ; Raoul, J L ; Clement, B ; Rolland, Y ; Boucher, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_13665624003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Cancer</topic><topic>Patients</topic><topic>Radiation therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garin, E</creatorcontrib><creatorcontrib>Lenoir, L</creatorcontrib><creatorcontrib>Edeline, J</creatorcontrib><creatorcontrib>Laffont, S</creatorcontrib><creatorcontrib>Mesbah, H</creatorcontrib><creatorcontrib>Porée, P</creatorcontrib><creatorcontrib>Sulpice, L</creatorcontrib><creatorcontrib>Boudjema, K</creatorcontrib><creatorcontrib>Mesbah, M</creatorcontrib><creatorcontrib>Guillygomarc'h, A</creatorcontrib><creatorcontrib>Quehen, E</creatorcontrib><creatorcontrib>Pracht, M</creatorcontrib><creatorcontrib>Raoul, J L</creatorcontrib><creatorcontrib>Clement, B</creatorcontrib><creatorcontrib>Rolland, Y</creatorcontrib><creatorcontrib>Boucher, E</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garin, E</au><au>Lenoir, L</au><au>Edeline, J</au><au>Laffont, S</au><au>Mesbah, H</au><au>Porée, P</au><au>Sulpice, L</au><au>Boudjema, K</au><au>Mesbah, M</au><au>Guillygomarc'h, A</au><au>Quehen, E</au><au>Pracht, M</au><au>Raoul, J L</au><au>Clement, B</au><au>Rolland, Y</au><au>Boucher, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Boosted selective internal radiation therapy with ^sup 90^Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><date>2013-07-01</date><risdate>2013</risdate><volume>40</volume><issue>7</issue><spage>1057</spage><pages>1057-</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with ^sup 90^Y-loaded glass microspheres (TheraSphere). TheraSphere was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p<0.001). With a threshold TD of 205 Gy, MAA SPECT/CT predicted response with a sensitivity of 100 % and overall accuracy of 90 %. Based on TD and HILD, 17 patients underwent treatment intensification resulting in a good response rate (76.4 %), without increased grade III liver toxicity. The median TTP and OS were 5.5 months (2-9.5 months) and 11.5 months (2-31 months), respectively, in patients with TD <205 Gy and 13 months (10-16 months) and 23.2 months (17.5-28.5 months), respectively, in those with TD >205 Gy (p=0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n=33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD <205 Gy and 10 months (6-15.2 months) and 21.5 months (12-28.5 months), respectively, in those with TD >205 Gy (p=0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n=6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved.[PUBLICATION ABSTRACT]</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00259-013-2395-x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2013-07, Vol.40 (7), p.1057 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_journals_1366562400 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Cancer Patients Radiation therapy |
| title | Boosted selective internal radiation therapy with ^sup 90^Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A55%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Boosted%20selective%20internal%20radiation%20therapy%20with%20%5Esup%2090%5EY-loaded%20glass%20microspheres%20(B-SIRT)%20for%20hepatocellular%20carcinoma%20patients:%20a%20new%20personalized%20promising%20concept&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Garin,%20E&rft.date=2013-07-01&rft.volume=40&rft.issue=7&rft.spage=1057&rft.pages=1057-&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-013-2395-x&rft_dat=%3Cproquest%3E2993321601%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1366562400&rft_id=info:pmid/&rfr_iscdi=true |